Ramamoorthy Nagasubramanian, MD

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., & Drilon, A. (2020). Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet Oncology, 21(4), 531-540. doi:10.1016/S1470-2045(19)30856-3

Janz, T. A., Nagasubramanian, R., & Wei, J. L. (2019a). A Survival Analysis of Pediatric Tonsillar Malignancies and Review of a Rare Case. International Journal of Pediatric Otorhinolaryngology, 118, 160-164. doi:10.1016/j.ijporl.2018.12.033

Janz, T. A., Nagasubramanian, R., & Wei, J. L. (2019b). Pediatric head and neck fibrosarcomas: A demographical, treatment, and survival analysis and review of a rare case. International Journal of Pediatric Otorhinolaryngology, 116, 92-96. doi:10.1016/j.ijporl.2018.09.031

DuBois, S. G., Laetsch, T. W., Federman, N., Turpin, B. K., Albert, C. M., Nagasubramanian, R., & Pappo, A. S. (2018). The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer, 124(21), 4241-4247. doi:10.1002/cncr.31701

Laetsch, T. W., DuBois, S. G., Mascarenhas, L., Turpin, B., Federman, N., Albert, C. M., & Hawkins, D. S. (2018). Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. The Lancet Oncology, 19(5), 705-714. doi:10.1016/S1470-2045(18)30119-0

Drilon, A., Laetsch, T. W., Kummar, S., Dubois, S. G., Lassen, U. N., Demetri, G. D., & Hyman, D. M. (2018). Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. New England Journal of Medicine, 378(8), 731-739. doi:10.1056/NEJMoa1714448

Laetsch, T. W., Nagasubramanian, R., & Casanova, M. (2018). Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma. Pediatric Blood and Cancer, 65(1). doi:10.1002/pbc.26593

Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., & Hyman, D. M. (2017). A next-generation TRK kinase inhibitor overcomes acquired resistance to prior trk kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discovery, 7(9), 963-972. doi:10.1158/2159-8290.CD-17-0507

Nagasubramanian, R., Wei, J., Gordon, P., Rastatter, J. C., Cox, M. C., & Pappo, A. (2016). Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatric Blood and Cancer, 63(8), 1468-1470. doi:10.1002/pbc.26026